Proteinuria

This trial asks whether mycophenolate mofetil (MMF) can help people with IgA nephropathy whose disease hasn't improved with standard care. About 104 adults with biopsy-confirmed refractory IgA nephropathy will be randomly assigned to take either MMF or the steroid prednisolone fo…

This study tests whether the drug finerenone can reduce protein in the urine (a sign of kidney damage) in adults with type 2 diabetes and chronic kidney disease. About 148 participants will receive either finerenone or a placebo pill daily for 6 months, on top of their usual medi…

This Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…

This study looks at whether routine blood test markers—like the Systemic Immune-Inflammation Index and platelet ratios—can help identify diabetic kidney disease in people with type 2 diabetes. Researchers will compare these markers across patients with different levels of albumin…

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either st…

This study tests whether Huaier Granules, a traditional Chinese medicine, can reduce proteinuria (excess protein in urine) caused by the cancer drugs bevacizumab or anlotinib in lung cancer patients. About 40 adults will be enrolled and followed for 16 weeks to see if the granule…

This study tests whether an electronic health record alert can help primary care doctors refer patients with blood and protein in their urine to a kidney specialist. About 1,200 adults with these high-risk signs will be included. The goal is to see if the alert improves referral …

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…